CoChat
Sign Up
Cited by 241

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Nanotechnology in Cancer Drug Delivery and Selective Targeting

Sutradhar, Kumar Bishwajit, Amin, Md. Lutful·2014·ISRN Nanotechnology
DOI 10.1155/2014/939378
Open this paper in CoChat — free account

Abstract

Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2014/939378

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Active and passive targeting by nanoparticles.
Figure 1 Active and passive targeting by nanoparticles.CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Image 6
CC-BY · From the PDF
Image 7
CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Image 9
CC-BY · From the PDF
Image 10
CC-BY · From the PDF
Image 11
CC-BY · From the PDF
Image 12
CC-BY · From the PDF
Image 13
CC-BY · From the PDF
Image 14
CC-BY · From the PDF
Image 15
CC-BY · From the PDF
Image 16
CC-BY · From the PDF
Image 17
CC-BY · From the PDF
Image 18
CC-BY · From the PDF
Image 19
CC-BY · From the PDF
Image 20
CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 113

  1. 10.1016/j.pharmthera.2010.07.007 · DOI
  2. 2013, International Journal of Nanomedicine, 8, 61
  3. 2012, International Journal of Nanomedicine, 7, 4391
  4. 10.3390/cancers3032888 · DOI
  5. 10.1038/nnano.2007.387 · DOI · Paper page
  6. 10.1016/j.tips.2009.08.004 · DOI
  7. 2013, European Journal of Nanomedicine, 5, 97
  8. 2007, Recent Patents on Drug Delivery & Formulation, 1, 37, 10.2174/187221107779814104 · DOI
  9. 10.1016/j.jconrel.2007.05.003 · DOI
  10. 10.1158/0008-5472.CAN-09-3716 · DOI
  11. 10.4172/2157-7439.1000103e · DOI
  12. 1983, European Journal of Cancer and Clinical Oncology, 19, 203, 10.1016/0277-5379(83)90418-2 · DOI
  13. 2002, Clinical Cancer Research, 8, 878
  14. 10.1016/S0928-0987(00)00114-7 · DOI
  15. 1999, Expert Reviews in Molecular Medicine, 1999, 1
  16. 1995, Annual Review of Genetics, 29, 607, 10.1146/annurev.ge.29.120195.003135 · DOI
  17. 10.1021/ar9703241 · DOI
  18. 2007, Annual Review of Biomedical Engineering, 9, 257, 10.1146/annurev.bioeng.9.060906.152025 · DOI · Paper page
  19. 10.1158/1078-0432.CCR-07-1441 · DOI
  20. 10.1016/S1470-2045(06)70793-8 · DOI
  21. 10.1038/nrc1958 · DOI
  22. 10.1038/nbt876 · DOI
  23. 10.1016/S0169-409X(02)00044-3 · DOI
  24. 1991, Journal of Colloid and Interface Science, 142, 149, 10.1016/0021-9797(91)90043-8 · DOI · Paper page
  25. 10.1039/b901729a · DOI
  26. 2004, Pure and Applied Chemistry, 76, 1321, 10.1351/pac200476071321 · DOI
  27. 10.1016/0169-409X(95)00039-A · DOI
  28. 10.1016/0169-409X(95)00022-Y · DOI
  29. 10.1504/WRSTSD.2007.013584 · DOI
  30. 10.1016/S0169-409X(99)00062-9 · DOI
  31. 10.1158/0008-5472.CAN-04-3921 · DOI
  32. 2012, Journal of Cancer Research Updates, 1, 1
  33. 10.3402/nano.v3i0.18496 · DOI · Paper page
  34. 10.1016/j.jconrel.2004.08.017 · DOI
  35. 10.1186/1471-2407-11-359 · DOI
  36. 2012, Biochimica et Biophysica Acta, 1820, 291, 10.1016/j.bbagen.2011.07.016 · DOI · Paper page
  37. 10.1021/bc034125f · DOI
  38. 10.1186/1475-2867-6-17 · DOI
  39. 10.1021/bc800249n · DOI
  40. 10.1073/pnas.0504274102 · DOI
  41. 10.1038/nrc903 · DOI
  42. 2001, Nature Reviews Cancer, 1, 118, 10.1038/35101072 · DOI
  43. 2004, Methods in Molecular Biology, 248, 201
  44. 1993, Bio/Technology, 11, 1145
  45. 10.1158/0008-5472.CAN-03-2732 · DOI
  46. 10.1073/pnas.0608491104 · DOI
  47. 10.1080/10611860400010697 · DOI
  48. 10.1038/sj.cgt.7700746 · DOI
  49. 1997, Journal of the National Cancer Institute, 89, 783, 10.1093/jnci/89.11.783 · DOI
  50. 2006, Cell Cycle, 5, 1779, 10.4161/cc.5.16.3018 · DOI
  51. 10.1023/A:1006446020377 · DOI
  52. 2000, Journal of the National Cancer Institute, 92, 94, 10.1093/jnci/92.2.94 · DOI
  53. 1992, Journal of the National Cancer Institute, 84, 1875, 10.1093/jnci/84.24.1875 · DOI
  54. 10.1111/j.1600-0463.2008.01148.x · DOI
  55. 10.2174/1568011053174882 · DOI
  56. 1991, The New England Journal of Medicine, 324, 1, 10.1056/NEJM199101033240101 · DOI
  57. 10.2174/1566524033479465 · DOI
  58. 10.1186/2045-824X-3-3 · DOI
  59. 10.1186/bcr589 · DOI
  60. 10.1242/jcs.00281 · DOI
  61. 10.1038/nrc2748 · DOI
  62. 2013, Journal of Biomedical Nanotechnology, 9, 1746, 10.1166/jbn.2013.1678 · DOI
  63. 2000, Magnetic Resonance in Medicine, 44, 433, 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9 · DOI · Paper page
  64. 10.1016/j.jconrel.2003.12.020 · DOI
  65. 10.1002/mrm.21794 · DOI
  66. 10.1038/sj.cgt.7700707 · DOI
  67. 1994, Princess Takamatsu Symposia, 24, 99
  68. 10.1159/000088479 · DOI
  69. 10.1016/S0169-409X(98)00003-9 · DOI
  70. 10.1073/pnas.95.8.4607 · DOI · Paper page
  71. 1966, Clinical Radiology, 17, 220, 10.1016/S0009-9260(66)80027-2 · DOI
  72. 1982, Journal of Cancer Research and Clinical Oncology, 103, 211, 10.1007/BF00409698 · DOI
  73. 10.1038/nrclinonc.2010.139 · DOI
  74. 10.1023/A:1025785505977 · DOI
  75. 10.1016/S0065-2571(00)00013-3 · DOI · Paper page
  76. 10.1016/S0168-3659(99)00248-5 · DOI · Paper page
  77. 10.1016/S1053-4296(98)80042-8 · DOI
  78. 10.1007/s000180300002 · DOI
  79. 2005, Oncology Reports, 13, 1003
  80. 10.1016/j.addr.2005.09.014 · DOI · Paper page
  81. 2012, The AAPS Journal, 14, 282, 10.1208/s12248-012-9339-4 · DOI · Paper page
  82. 10.1016/S0142-9612(99)00125-8 · DOI
  83. 2013, Drug Target Insights, 7, 27
  84. 10.1016/S0168-3659(01)00460-6 · DOI
  85. 2004, British Journal of Cancer, 90, 2085, 10.1038/sj.bjc.6601856 · DOI · Paper page
  86. 1996, British Journal of Cancer, 74, 1545, 10.1038/bjc.1996.587 · DOI
  87. 2000, Clinical Cancer Research, 6, 1949
  88. 10.1016/j.ijpharm.2009.04.037 · DOI
  89. 10.1016/j.ejps.2009.07.006 · DOI
  90. 10.1016/j.biomaterials.2008.09.056 · DOI · Paper page
  91. 10.1016/j.ejmech.2008.04.021 · DOI
  92. 10.1016/j.biomaterials.2009.09.036 · DOI
  93. 10.1016/j.jconrel.2009.06.019 · DOI
  94. 10.1016/j.jconrel.2009.01.021 · DOI
  95. 10.1155/2011/408675 · DOI
  96. 2010, International Journal of Pharmaceutical Sciences and Nanotechnology, 3, 1043, 10.37285/ijpsn.2010.3.3.2 · DOI
  97. 10.1016/j.urolonc.2007.03.015 · DOI
  98. 1996, Nature, 380, 561, 10.1038/380561a0 · DOI
  99. 1979, Journal of Pharmaceutical Sciences, 68, 451, 10.1002/jps.2600680415 · DOI
  100. 1991, Proceedings of the National Academy of Sciences of the United States of America, 88, 11460, 10.1073/pnas.88.24.11460 · DOI
  101. 10.1002/ijc.11615 · DOI
  102. 2001, Cancer Research, 61, 2592
  103. 2012, Nanomedicine: Nanotechnology, Biology, and Medicine, 8, S21, 10.1016/j.nano.2012.05.011 · DOI
  104. 10.1002/ijc.22709 · DOI
  105. 10.1163/156855206775123494 · DOI
  106. 1980, Science, 210, 1253, 10.1126/science.7434025 · DOI
  107. 1994, Cancer Research, 54, 2186
  108. 10.1016/j.nano.2005.03.002 · DOI
  109. 10.1146/annurev-med-040210-162544 · DOI
  110. 2005, Nanomedicine: Nanotechnology, Biology and Medicine, 1, 22, 10.1016/j.nano.2004.11.009 · DOI
  111. 10.1021/bc0000583 · DOI · Paper page
  112. 10.1158/0008-5472.CAN-08-1468 · DOI
  113. 10.1016/j.cbpa.2005.10.005 · DOI

Cited by

Sorted by citations

See all 241

Metadata

Authors
Sutradhar, K. B., & Amin, M. L.
Venue
ISRN Nanotechnology
Publisher
Hindawi Limited
Published
2014-01-16
Volume
2014
Pages
1-12
ISSN
2090-6072
DOI
10.1155/2014/939378
Cited by
241
References
5
Language
en
Licence
creativecommons.org/licenses/by/3.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review